🔎 Trials Near Me

Beranda › Leukemia Mieloid Akut › Alabama › Birmingham

Uji klinis Leukemia Mieloid Akut di Birmingham, AL

21 studi untuk Leukemia Mieloid Akut mencari peserta di lokasi sekitar Birmingham (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Menerima pesertaFase 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Menerima pesertaFase 3
  • University of Alabama at Birmingham, Birmingham
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Menerima pesertaFase 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Menerima pesertaFase 1
  • Children's Hospital of Alabama, Birmingham
Hingga usia 21 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Menerima pesertaFase 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Menerima pesertaFase 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Menerima pesertaFase 3
  • Children's Hospital of Alabama, Birmingham
6 Months – 21 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04293562

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Menerima pesertaFase 2
  • University of Alabama - Birmingham, Birmingham
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06824168

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Menerima pesertaFase 3
  • Children's Hospital of Alabama, Birmingham
Usia 1 hingga 25 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07022678

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Menerima pesertaFase 1/2
  • O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT04588922

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Menerima pesertaFase 2/3
  • University of Alabama Birmingham, Birmingham
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06788756

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Menerima pesertaStudi observasional
  • University of Alabama at Birmingham, Birmingham
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Menerima peserta
  • University of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT06697600

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Menerima pesertaFase 1
  • University of Alabama at Birmingham, Birmingham
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 4 Mar 2026 · NCT07044544

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Menerima pesertaFase 1
  • University of Alabama O'Neal Cancer Center, Birmingham
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jan 2026 · NCT05143996

HPC Offered for PRESERVE Expansion

Menerima pesertaStudi observasional
  • University of Alabama, Birmingham, Birmingham
Usia 12 hingga 80 · Semua jenis kelamin · Diperbarui 28 Agu 2025 · NCT07145411

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Menerima pesertaFase 1/2
  • The Kirklin Clinic of UAB Hospital, Birmingham
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2025 · NCT03850574

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Menerima pesertaSukarelawan sehat diterima
  • University of Alabama - Birmingham, Birmingham
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 25 Jul 2025 · NCT05237258

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Menerima pesertaFase 1
  • University of Alabama at Birmingham, Birmingham
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Nov 2024 · NCT06034275

Uji klinis Leukemia Mieloid Akut di kota lain

Studi lain di Birmingham

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.